PHC Live Cell Metabolic Analyzer (LiCellMo) Wins 2024 Innovation Award

TOKYO — The Biomedical Division of PHC Corporation, based in Chiyoda-ku, Tokyo, Japan, has been honored with a prestigious 2024 Innovation Award from The Analytical Scientist for its groundbreaking product, the LiCellMo^TM, a live cell metabolic analyzer. This innovative device was launched for research applications in Japan in September, followed by its introduction in the United States, the UK, the EU, China, and selected Asian regions in October.

The LiCellMo is engineered to provide real-time data on essential cellular metabolic pathways. This capability gives researchers an unprecedented view of previously hidden changes in cellular states over time, thus enabling them to make better-informed decisions in their research. This tool is anticipated to significantly contribute to new research discoveries and advancements in therapeutic developments.

Understanding LiCellMo's Impact on Research

The primary function of LiCellMo is to expose cellular metabolic mechanisms and enhance the reproducibility and quality of cell cultures used in the development of cell and gene therapy products. Traditional methods often require researchers to periodically sample the culture medium to gauge cell metabolism, a process that can disrupt cell conditions and risk contamination.

LiCellMo changes this paradigm by providing continuous minute-by-minute measurements of glucose and lactate in the culture medium, allowing researchers to receive instant feedback on cellular activity. Its design enables straightforward integration into existing CO₂ incubators with no changes necessary to the typical culture environment, making it a versatile addition to laboratory setups.

The Future of Cell and Gene Therapy Research

In an interview, Chikara Takauo, Director of PHC Corporation and Head of the Biomedical Division, expressed confidence that LiCellMo will empower researchers to uncover crucial insights into cell metabolism, particularly in fields like cancer immunology and stem cell research. This recognition of LiCellMo not only highlights its immediate benefits to research laboratories but also its potential in accelerating the development of innovative therapies.

PHC Corporation is part of the larger PHC Holdings Corporation group, a collection of global healthcare companies. The in-line monitoring technology utilized by LiCellMo is based on proprietary technology stemming from the In Vitro Diagnostics (IVD) Division's work on blood glucose monitoring sensors.

About PHC Corporation and Its Vision

Established in 1969, PHC Corporation focuses on advancing healthcare solutions and supporting the life sciences industry. Their products and services, marketed under the PHCbi brand, are utilized in over 110 countries, with offerings including CO₂ incubators and ultra-low temperature freezers.

PHC Group aims to impact society positively through healthcare solutions that enhance people's lives. With consolidated net sales of JPY 353.9 billion in FY2023, PHC Group plays a significant role in the distribution of healthcare products and services globally.

healthcare, innovation, research